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The Children’s Health Act (2000) authorized
the National Children’s Study (NCS) to study
the long-term effects of the environment on
children’s health and development by examin-
ing children across the United States from
before birth to 21 years of age (Branum et al.
2003). One of the top priorities of the NCS
was to identify factors responsible for the
increasing rise of neurodevelopmental disor-
ders (e.g, learning disabilities, mental retarda-
tion, attention deﬁcit disorder) (Branum et al.
2003). Because brain development begins
early in fetal life and continues until adoles-
cence, exposure to environmental chemicals at
this early age may be a leading cause of neuro-
developmental disorders. In support, a report
by the National Research Council recently
concluded that 3% of developmental disabili-
ties are the direct consequence of exposure to
environmental neurotoxins and that another
25% arise out of the interplay between envi-
ronmental factors and genetic susceptibility
(Landrigan et al. 2004). These conclusions
were derived from data collected on children
who had been exposed to established neuro-
toxic agents (e.g., alcohol, pesticides, heavy
metals, polychlorinated biphenyls). However,
many of the chemicals identified by the
Chemical Agents Working Group of the NCS
are genotoxicants and therefore are capable of
directly or indirectly damaging DNA to
induce long-term neurologic impairment.
Although DNA damage is a characteristic
feature of certain neurodevelopmental dis-
orders (Nishioka and Arnold 2004) or neuro-
logic disease (Alam et al. 1997; Lyras et al.
1997; Mecocci et al. 1994, 1997), our under-
standing of how genotoxicants may contribute
to these conditions is poorly understood. 
The complex and hierarchical cytoarchitec-
ture of the mature brain is the culmination of a
sequence of biochemical and molecular events
tightly controlled by speciﬁc patterns of gene
expression. Regions of the central nervous sys-
tem (CNS) develop at different stages and this
correlates with a distinct sequence of events
that includes cell proliferation, migration, and
differentiation or maturation. Interference at
any one of these stages of development would
be expected to induce permanent impairment.
Because most neurodevelopmental disorders
are categorized as migrational disorders
(Gleeson 2001), environmental agents that
preferentially target the DNA of immature
postmitotic neurons would be expected to dis-
rupt the transcriptional events that control the
key steps involved in laying down the final
cytoarchitecture of the mature brain.
Identifying the key molecular networks specif-
ically targeted by genotoxicants in immature
postmitotic neurons could provide an impor-
tant ﬁrst step in understanding how this class
of environmental agents influences brain
development. 
Methylazoxymethanol (MAM) and
nitrogen mustard (HN2) are two established
genotoxicants that reproducibly disrupt neu-
ronal development when administered during
the fetal or neonatal period of CNS develop-
ment (Cattabeni and Di Luca 1997; Ferguson
1996; Graef et al. 1948; McDonald and
Asano 1961). The glucoside form of MAM
(i.e, cycasin) is also strongly linked to a proto-
typical neurologic disorder found in the west-
ern Pacific with features of amyotrophic
lateral sclerosis, Parkinson disease and an
Alzheimer-like dementia (ALS/PDC; Spencer
et al. 1991; Zhang et al. 1996). These studies
suggest that early life exposure to a genotoxi-
cant is associated with neurodevelopmental or
neurodegenerative changes. The genotoxic
properties of MAM have been widely used by
neurobiologists to selectively target neurons
during CNS development (Cattabeni and Di
Luca 1997; Colacitti et al. 1999), whereas the
chemotherapeutic agent HN2 induces imme-
diate and delayed neurotoxicity in humans
(Sullivan et al. 1982) and is a potent experi-
mental teratogen [Sullivan et al. 1982; see also
review by Spencer et al. (1999)]. Rodents
treated with MAM or HN2 in utero or within
1–5 days of birth show strikingly abnormal
development of the cerebral cortex (Balduini
et al. 1986; Cattabeni and Di Luca 1997;
Ferguson and Holson 1997) or cerebellum
(Ferguson et al. 1996; Sullivan-Jones et al.
1994), respectively, and exhibit changes in
motor or cognitive function. Prenatal expo-
sure to MAM is characterized by cortical atro-
phy (Colacitti et al. 1999), an increased
susceptibility to epileptogenic agents (Baraban
and Schwartzkroin 1996; Chevassus-Au-Louis
et al. 1999; DeFeo et al. 1995; Jacobs et al.
1999), an age-dependent decline in learning
and memory (Matijasevic et al. 1993; Vorhees
et al. 1984), and an impaired social behavior
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BACKGROUND: Exposure of the brain to environmental agents during critical periods of neuronal
development is considered a key factor underlying many neurologic disorders. 
OBJECTIVES: In this study we examined the inﬂuence of genotoxicants on cerebellar function during
early development by measuring global gene expression changes. 
METHODS: We measured global gene expression in immature cerebellar neurons (i.e., granule cells)
after treatment with two distinct alkylating agents, methylazoxymethanol (MAM) and nitrogen
mustard (HN2). Granule cell cultures were treated for 24 hr with MAM (10–1,000 µM) or HN2
(0.1–20 µM) and examined for cell viability, DNA damage, and markers of apoptosis. 
RESULTS: Neuronal viability was signiﬁcantly reduced (p < 0.01) at concentrations > 500 µM for
MAM and > 1.0 µM for HN2; this correlated with an increase in both DNA damage and markers of
apoptosis. Neuronal cultures treated with sublethal concentrations of MAM (100 µM) or HN2
(1.0 µM) were then examined for gene expression using large-scale mouse cDNA microarrays
(27,648). Gene expression results revealed that a) global gene expression was predominantly up-regu-
lated by both genotoxicants; b) the number of down-regulated genes was approximately 3-fold greater
for HN2 than for MAM; and c) distinct classes of molecules were inﬂuenced by MAM (i.e, neuronal
differentiation, the stress and immune response, and signal transduction) and HN2 (i.e, protein syn-
thesis and apoptosis). 
CONCLUSIONS: These studies demonstrate that individual genotoxicants induce distinct gene
expression signatures. Further study of these molecular networks may explain the variable response
of the developing brain to different types of environmental genotoxicants.
KEY WORDS: cerebellum, DNA damage, granule cell, HN2, MAM, methylazoxymethanol, nitrogen
mustard. Environ Health Perspect 114:1703–1712 (2006). doi:10.1289/ehp.9073 available via
http://dx.doi.org/ [Online 7 September 2006]that bears resemblance to that seen in schizo-
phrenia (Flagstad et al. 2005; Talamini et al.
1998, 1999). When MAM is administered
after birth (1–4 days), the effects are conﬁned
primarily to the cerebellum (Ferguson 1996;
Sullivan-Jones et al. 1994). This exposure also
leads to atrophy that is characterized by speciﬁc
targeting of glutaminergic and GABAergic pre-
cursor cells of the cerebellum (especially gran-
ule cells) resulting in misalignment of Purkinje
cells and ectopic and multinucleated granule
cells. Multinucleated and ectopic neurons have
also been reported in the cerebellum and
vestibular nuclei of subjects with ALS/PDC
(Shiraki and Yase 1975), an observation that
suggests human exposure to MAM during
early CNS development may have arrested the
mitotic and migratory developmental responses
of neurons. 
Gene expression proﬁling is becoming an
increasingly useful approach for elucidating
complex relationships between toxins and the
patterns of plasticity during CNS develop-
ment (Mody et al. 2001; Poguet et al. 2003)
or for understanding the full impact of envi-
ronmental toxins on cells or tissues (Amin
et al. 2002; Mandel et al. 2002). For example,
gene expression profiling has been used
recently to dissect the complex mechanisms
underlying CNS injury in several neurodevel-
opmental disorders (e.g., epilepsy, schizophre-
nia, learning disabilities) (Becker et al. 2002;
Mirnics et al. 2000) and in neurodegenerative
disease (Ishigaki et al. 2002; Pasinetti 2001).
Because the majority of neurodevelopmental
disorders in children occur during the migra-
tion of immature neurons, gene expression
proﬁling was used to identify the speciﬁc mol-
ecular networks targeted by MAM or the
related alkylating agent HN2 in cultures of
young postmitotic cerebellar neurons. 
Materials and Methods
Neuronal and astrocyte cell cultures. We pre-
pared primary mouse granule and astrocyte cell
cultures from the cerebella of 6- to 8-day-old
neonatal C57BL/6 (Charles River Laboratories,
Wilmington, MA) mice by placing the tissues
in ice-cold Hibernate/B27 cell culture media
(Invitrogen Corp., Carlsbad, CA) and dissociat-
ing the tissue in balanced salt solution with
0.1% trypsin as previously described (Kisby
et al. 2000, 2004; Meira et al. 2001). The cell
suspension was placed in poly-D-lysine coated
(Biocoat; BD Biosciences, Bedford, MA)
48-well plates (viability studies), 8-well cham-
ber slides [terminal deoxynucleotidyl trans-
ferase-mediated biotinylated-UTP nick
end-labeling (TUNEL)], or 6-well plates (DNA
damage) at a density of 0.07 × 106/well (8-well
chamber slides and 48-well plates) or 1 × 106
cells/well (6-well plates), respectively. We fed
cell cultures weekly by adding fresh culture
media to the wells and maintained the cells for
7 days (neurons) or 3–4 weeks (astrocytes)
before treatment with 10–1,000 µM MAM or
0.1–20 µM mechlorethamine hydrochloride
(HN2). All animals used in these studies were
treated humanely and with regard to the allevia-
tion of suffering according to protocols
approved by the Oregon Health & Science
University Institutional Animal Care and Use
Committee.
Cell viability. Mouse neuronal and astro-
cyte cell cultures treated with control media or
media supplemented with various concentra-
tions of MAM or HN2 were examined for cell
viability using the ﬂuorochrome acetoxymethyl
ester, as previously described (Kisby et al.
2004; Meira et al. 2001). The ﬂuorochrome-
containing media was aspirated, the cultures
washed once with control media, and cell sur-
vival examined on a fluorescence microplate
reader (GeminiXS; Molecular Devices,
Sunnyvale, CA) with well-scan capabilities.
Values were expressed as the mean percent sur-
viving of control cells ± SE (n = 6/treatment
group × 3–5 separate experiments).
DNA damage. N7-Alkylguanine levels.
We isolated and puriﬁed DNA from MAM- or
HN2-treated cerebellar neuronal cell cultures
by extracting the tissue with Tri-Reagent
(Molecular Research Corp., Cincinnati, OH)
according to the manufacturer’s instructions.
DNA concentration ranged between 20 and
30 µg/1 × 106 cells, and the purity was checked
by measuring 260/280 ratios (range 1.7–2.0).
An alkylated DNA standard was prepared by
treating calf thymus DNA (CT-DNA) with
1 mM MAM in buffer [300 mM MOPS,
2 mM EDTA (pH 7.5)] for 1 hr at 37°C.
DNA samples and alkylated CT-DNA were
depurinated by incubating in 0.1 N HCl for
17 hr at 37°C. The depurinated samples and
standards were neutralized with 1.0 N NaOH,
passed through a C18 SepPak cartridge
(Millipore Corp., Bedford, MA), and taken to
dryness in a speed-vac. The lyophylized sam-
ples and alkylated DNA were analyzed for
N7-methylguanine (N7-mG) or N7-alkylgua-
nine [i.e, N-(2-hydroxyethyl)-N-(2-(7-
guaninyl)ethyl)-methylamine (GMOH)] DNA
lesions by HPLC with electrochemical detec-
tion as previously described by Eizirik and
Kisby (1995), Esclaire et al. (1999), and Kisby
et al. (2000). Alkylated DNA was used to
determine recovery (> 90%) of N7-mG and
GMOH from the extraction process. N7-mG
and GMOH levels were determined in samples
and from a standard curve (r = 0.99) of
CT-DNA alkylated with MAM or HN2,
respectively. Values are expressed as fmoles
N7-mG or GMOH per microgram DNA.
TUNEL labeling. Primary cerebellar neu-
ronal cultures treated for 24 hr with MAM or
HN2 were examined for DNA fragmentation
using TUNEL with the NeuroTacs staining kit
according to the manufacturer’s instructions
(Trevigen, Gaithersburg, MD). After toxin
treatment, the cells were fixed with 4%
buffered paraformaldehyde, and the incorpora-
tion of biotinylated nucleotides was visualized
by incubating the cells with NovaRed (Vector
Labs, Inc, Burlingame, CA). Slides were lightly
counterstained with methyl green and the cells
examined by light microscopy as previously
described (Kisby et al. 2004). 
Microarrays. We purchased 27,648
sequence-verified mouse cDNA clones from
Research Genetics [Brain Molecular Anatomy
Project  (BMAP) clones; Invitrogen Corp.]
and The National Institute of Aging (NIA
clones; Bethesda, MD) as frozen bacterial
stocks were used to create two individual
arrays (13,824 genes/array) spanning nearly
the entire mouse genome. Universal forward
and reverse primers were amino modiﬁed with
a 5´ C12 spacer. Polymerase chain reaction
(PCR) products were puriﬁed using Telechem
PCR clean-up plates, dried down, and resus-
pended in 20 µL Telechem spotting solution
and printed on TeleChem SuperAldehyde
substrates using a Cartesian Pixsys printer with
quill pins from TeleChem International
(Sunnyvale, CA).
RNA preparation. We isolated RNA from
cerebellar neuronal cultures treated for 24 hr
with 100 µM MAM or 1.0 µM HN2 using
Tri-Reagent (Molecular Research Corp.)
according to the manufacturer’s protocol.
Because  RNA concentrations were low
(10–15 µg/well for 6-well plate), two wells
were combined, and each combined sample
(n = 3) was analyzed for gene expression using
mouse cDNA microarrays. We used bromo-
chloropropane for the initial phase separation.
RNA was dissolved in water that had been
treated with diethyl pyrocarbonate to ensure
that it was RNAse free and quantitated based
on optical density (OD)260. 
Gene arrays processing. RNA (10 µg) was
reverse transcribed using 2 µg of oligo dT
primer (24mer) in the presence of 200 mM
dNTP mixture (dATP, dGTP, dCTP),
100 mM dTTP, 100 mM 5-(3-aminoallyl)-
2´-deoxyuridine-5´-triphosphate (Sigma
Chemical Corp., St. Louis, MO) and 300 U
of Superscript II (Invitrogen, Carlsbad, CA) to
generate aminoallyl-modified cDNA probes.
After hydrolysis of the original RNA, we used a
Qiagen PCR cleanup kit (Qiagen, Valencia,
CA) with a modified protocol to purify the
cDNA product. The cDNA probe was then
dried down and resuspended in 0.1 M NaCO2
buffer (pH 9.0) and coupled to N-hydroxysuc-
cinimide ester cyanine 5 dye (GE Healthcare,
Piscataway, NJ) in the presence of dimethyl-
sulfoxide. The uncoupled dye was removed
using a Qiagen PCR cleanup kit according to
the the manufacturer’s protocol. The puriﬁed
cDNA probe was lyophilized and resuspended
in 70 µL of Ribohybe (Ventana, Tucson, AZ).
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lifterslip (Erie Scientiﬁc, Portsmouth, NH) and
allowed to hybridize in a humidity chamber for
16 hr at 50°C. Each sample was hybridized
separately to two arrays with distinct sets of
cDNA probes (one set from the BMAP clones
and one from the NIA clone set). The com-
bined data from the two probe sets explore the
variation in gene expression with 27,265
unique clones. Microarrays were washed with
2×SSC [300 mM NaCl, 30 mM sodium citrate
(pH 7.0)] on a rocker 2 × 10 min at room tem-
perature followed by two washes for 10 min
each in 0.2×SSC at 50°C to remove unbound
probe. Microarrays were dried by centrifuga-
tion. Tagged image file format (.tif) images
were collected using a SA5000 fluorescence
scanner (PerkinElmer, Wellesley, MA) and the
data collected and analyzed with QuantArray
data collection software (PerkinElmer). Signal
extraction protocols exported the mean pixel
intensity of the upper 65% of signal pixels and
the mean pixel intensity of the lower 65% of
background pixels. 
Data analysis. We adjusted mean signal
intensity for local background by subtracting
the mean background intensity. Data for each
array set were exported to Arraystat statistical
software (Imaging Research, version 1.0, revi-
sion 2.0; GE Healthcare). The Arraystat nor-
malization parameters used were “proportional
model with offsets, no outlier exclusion,”
which log transforms the data (log10) and glob-
ally centers the transformed data within condi-
tions by subtracting the array mean for all
genes present on all arrays in the condition and
adding the condition mean for all arrays in the
condition. Condition means were globally cen-
tered by subtracting the median of the mean
signal intensities for the condition and adding
the median of the mean signal intensities across
all conditions. Modified analysis of variance
(ANOVA) (Arraystat F* tests) and signiﬁcance
of differences between means (z-tests) were
determined using a pooled error model.
Centered expression values and test results
were exported to Microsoft Excel (Microsoft
Corp., Redmond, WA). We converted nor-
malized means and differences between means
from log10 to log2 for ease of comparison with
the literature. Data sets were merged and
adjustment for multiple testing was conducted
on the p-values of the statistical tests in the
merged data set using the false discovery rate
correction with the level of acceptable false
positives set at 0.05 for each statistical test
(Benjamini and Hochberg 1995). The full set
of MAM- and HN2-targeted genes can be
found online in Supplemental Material
(http://www.ehponline.org/docs/2006/9073/
suppl.pdf).
Results
Viability and DNA damage in immature 
neurons. In the present study, our goal was to
determine the relationship between the sensi-
tivity of immature postmitotic neurons to
MAM or HN2 and their ability to damage
DNA. For these studies, we treated neuronal
cell cultures from the cerebellum of neonatal
mice with various concentrations of MAM or
HN2 for 24 hr and examined them for cell
survival (Figure 1A,B). We also similarly
treated astrocytes with MAM and HN2 to
compare the vulnerability of different CNS cell
types to genotoxicants. Survival of cerebellar
neurons was signiﬁcantly reduced with increas-
ing concentrations of MAM (> 100 µM) or
HN2 (> 5.0 µM). In contrast, astrocytes
derived from the same set of animals were sig-
niﬁcantly less sensitive (p < 0.01) to MAM or
HN2. These studies demonstrate that imma-
ture neurons are more sensitive to MAM or
HN2 than astrocytes, which suggests that this
CNS cell type would be preferentially targeted
in vivo by these genotoxicants. 
Additional studies were conducted to
determine if the increased sensitivity of neu-
rons to MAM and HN2 was due to their
genotoxic (i.e., DNA damaging) properties.
DNA damage was assessed by measuring the
level of N7-mG or GMOH, the two major
DNA lesions formed by MAM and HN2
(Nagata and Matsumoto 1969; Osborne et al.
1995), or strand breaks (TUNEL labeling).
There was a good correlation between the
increased sensitivity of neurons to these geno-
toxicants and TUNEL labeling (Figure 2A) or
the level of N7-mG and GMOH DNA
lesions (Figure 2B,C). These studies demon-
strate that the major DNA lesions formed by
MAM or HN2 accumulate in immature neu-
rons and that these cells are particularly inefﬁ-
cient at repairing these types of DNA lesions.
Thus, N7-mG and GMOH are likely respon-
sible for the neurotoxic effects of these geno-
toxicants observed in Figure 1. These ﬁndings
are also consistent with previous in vitro and
in vivo studies, demonstrating that the
increased sensitivity of rat cerebellar neurons
or differentiated human SY5Y neuroblastoma
cell cultures to HN2 correlated with GMOH
levels (Kisby et al. 2000) and N7-mG levels
were elevated in the dystrophic cerebellum of
neonatal or fetal mice injected with MAM
(Kisby et al. 1999, 2005) or other alkylating
agents (Buecheler and Kleihues 1977;
Kleihues and Bucheler 1977). 
Genotoxicants induce neuronal molecular signatures
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Figure 1. Comparative sensitivity of neurons and astrocytes to MAM or HN2. Representative epifluores-
cence micrographs of cultures of cerebellar neurons (A) and astrocytes (B). Bars = 50 μm (A) and
100 μm (B). Cultures of murine cerebellar granule cells (C,E) and astrocytes (D,F) were treated with various
concentrations of MAM (10–1,000 μM) or HN2 (0.1–20 μM) for 24 hr, incubated with calcein acetoxymethyl
ester and the cells examined for ﬂuorescence. Values represent the mean percent survival of controls ± SE
(n = 6/treatment, 2–3 experiments). 
Signiﬁcantly different from control cells (*p < 0.01) or genotoxicant-treated astrocytes (**p < 0.01 by ANOVA). 
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changes. Collectively, the studies described
above and the previous work with these 
genotoxicants (Dacre and Goldman 1996;
Matsumoto et al. 1972; Somani and Babu
1989) indicate that neuronal DNA is a sensitive
intracellular target. Failure to repair these DNA
lesions would be expected to interfere with
transcription and translation (Scicchitano and
Mellon 1997; Scicchitano et al. 2004), resulting
in perturbed cell function and eventual death
via an apoptotic or necrotic mechanism
(Dabrowska et al. 1996; Hur et al. 1998; Meier
and Millard 1998; Sun et al. 1999). To identify
the specific molecular networks targeted by
MAM or HN2, we examined genotoxicant-
treated neurons for genomewide expression
using high-density mouse cDNA microarrays
(Figure 3). Our objective here was to determine
if these genotoxicants induce a distinct pattern
of gene expression at concentrations that are
sublethal (Figure 1) and that induce DNA
damage (Figure 2B,C). Using these criteria, we
treated cerebellar neuronal cultures with
100 µM MAM or 1.0 µM HN2 for 24 hr and
examined total RNA for gene expression
changes using high-density microarrays. We
then compared the gene expression proﬁles of
MAM- and HN2-treated neurons to character-
ize the response of immature neurons to the
two different genotoxicants.
We first used hierarchical clustering
(Euclidean distance measure and centroid link-
age) to group genes with similar expression lev-
els. Several of these clusters are also speciﬁcally
enriched with genes of known function. As
shown in the heatmap (Figure 3A), we
observed distinct clusters for MAM and HN2.
The number of genes uniquely regulated by
each genotoxicant and their overlap is shown
in Figure 3B. The global expression patterns
were analyzed further by functional classes of
molecules such as DNA repair, cell signaling,
proteasome degradation, apoptosis to ﬁnd cor-
relations among genes and gene-regulatory net-
works (Figure 3C,D). The global gene
expression changes we observed after MAM
(606 genes, 2.19%) and HN2 (617 genes,
2.23%) treatment were comparable. Of these
global changes, 397 unique genes (64%) were
altered by MAM, whereas a similar amount of
unique genes (408 genes, 66%) were altered by
HN2. Although comparable numbers of
unique genes were up-regulated by either
MAM or HN2, approximately 3 times as
many were down-regulated by HN2 as by
MAM (Figure 3B). Among the down-regulated
genes, those involved in apoptosis (9.5%) and
protein synthesis (4.8%) were targeted by
HN2 (n = 21), whereas MAM (n = 10) pri-
marily targeted those involved in signal trans-
duction (30%), cell adhesion (20%), and
growth and cell cycle (10%). These studies
indicate that MAM and HN2 target distinct
classes of genes in neurons even though both
agents alkylate DNA (i.e., the N7 site on gua-
nine) and induce a similar global effect on neu-
ronal gene expression. The selective targeting
of these functional classes of genes by HN2
and MAM may be related to the different
types of DNA lesions generated by these two
gentotoxicants; notably, HN2 induces lethal
cross-links between opposing N7-alkylgua-
nines (i.e., GMOH) (Osborne et al. 1995;
Povirk and Shuker 1994; Tokuda and Bodell
1987), whereas MAM induces methylated
DNA lesions (e.g., N7-mG and O6-mG)
(Esclaire et al. 1999; Matsumoto and Higa
1966; Nagata and Matsumoto 1969). The
insensitivity of cerebellar neurons to similar
concentrations of 2-chloroethylamine (CEA;
data not shown), a monofunctional analogue
of HN2 that does not induce cross-links
(Tokuda and Bodell 1987; Wijen et al. 2000)
and the elevated levels of N7-mG DNA lesions
in MAM-treated cortical neurons with dis-
turbed tau gene expression (Esclaire et al.
1999) are consistent with this hypothesis. 
Functional classes targeted by MAM and
HN2. Even though the majority of genes
influenced by sublethal concentrations of
MAM or HN2 were of unknown function
(63 and 77%, respectively), analysis of the
known genes perturbed by MAM (225 genes)
or HN2 (141 genes) revealed prominent
changes in several different categories
(Figure 3C,D), indicating that the molecular
networks targeted by these two genotoxicants
are quite distinct. As shown in Figure 3C,
MAM had a greater influence on genes
involved in neuronal differentiation, the stress
and immune response, signal transduction,
and transcriptional regulation. In contrast,
HN2 primarily targeted genes involved in
apoptosis and protein synthesis. As expected,
MAM had a predominant effect on neuronal
differentiation, which was demonstrated by
the targeting of a large number of genes that
control the growth and maturation of neurons
(Table 1). Genes that maintain the structural
integrity of neurons (Prfn2, Sdfr1, Catna1,
Stmb2), cellular transport (Slc6a6, Kif1A),
protein degradation (Usp5, Ufd1l, Usp2l,
Psmd12), or synaptic function (Vamp4, Cplx2)
were specifically targeted by MAM. The
increased expression of genes that activate the
Kisby et al.
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Figure 2. In situ DNA damage of cerebellar neurons treated with MAM or HN2. (A–C) Representative light
micrographs of cerebellar neurons treated for 24 hr with various concentrations of MAM or HN2 and
examined for the extent of DNA fragmentation by TUNEL labeling (A) or N7-alkylguanine DNA lesions
induced by 100 μM MAM (B) or 0.1–10 μM HN2 (C). Note the extensive labeling of neurons treated with
10 μM HN2 or 1,000 μM MAM. Bar = 50 μm. 
Signiﬁcantly different from control-treated neurons (*p < 0.05 or **p < 0.01 by ANOVA).
A
Control 1,000 μM MAM 10 μM HN2
80
60
40
20
0
0 10 100 1,000
MAM (μM)
**
B C
HN2 (μM)
80
60
40
20
0
0 1
10
8
6
4
2
0
P
e
r
c
e
n
t
 
T
U
N
E
L
+
 
c
e
l
l
s
f
m
o
l
 
N
7
-
m
G
/
μ
g
 
D
N
A
f
m
o
l
 
G
M
O
H
/
μ
g
 
D
N
A
100
80
60
40
20
0
Control MAM
*
Control
**
0.1
**
1.0
**
10
HN2 (μM)
5
**
10
**
P
e
r
c
e
n
t
 
T
U
N
E
L
+
 
c
e
l
l
sdepolymerization of actin (Prfn2) and micro-
tubules (Stmb2) (Grenningloh et al. 2004;
Yarmola and Bubb 2006) is consistent with
the ability of MAM to disrupt the outgrowth
of axons (Hoffman et al. 1996) and to alter
the inward and vertical migration of granule
cells through the developing molecular and
Purkinje cell layers of the neonatal cerebellum
(Ferguson et al. 1996; Kisby et al. 2004). The
strong up-regulation of the serine–threonine
kinase Ulk1 and the zeta isoform of protein
kinase c (Prkcz), which are important regula-
tors of neurite sprouting (Naik et al. 2000;
Tomoda et al. 2004), is additional evidence of
how this genotoxicant may impede the migra-
tion of immature neurons (Hatten 2002). 
Although a majority of the genes targeted
by MAM were involved in neuronal differenti-
ation, the strongest response was observed for
chromatin remodeling (H3f3a) (Frank et al.
2003) and energy metabolism (e.g., complex I,
glycolytic enzymes) genes. The pronounced
targeting of H3f3a suggests that MAM 
may inﬂuence transcription by disturbing the
nucleosome structure through a chromatin
remodeling mechanism (McKittrick et al.
2004). Therefore, the protein encoded by this
histone gene may function to maintain chro-
matin integrity in immature neurons or might
be involved with transcription or DNA repair.
A corresponding increase in the expression of
Ezh2, a gene that controls the expression of
genes through methylation of H3 (Kirmizis
et al. 2004), is consistent with this notion.
Unexpectedly, MAM also produced a pro-
nounced effect on the expression of two cata-
lytic subunits (i.e., Ndufc1, Ndufs5) of
complex I (Kirby et al. 2004; Loeffen et al.
1998) and several glycolytic enzymes (Idh,
Pk3), indicating that this genotoxicant also dis-
turbs energy metabolism. The influence of
MAM on energy metabolism may explain how
this genotoxicant induced lipid peroxidation in
the colon and liver of rats (Deschner and
Zedeck 1986) and why this effect was counter-
acted by pretreatment with the antioxidant
quercetin (Deschner et al. 1991, 1993). 
Even though MAM and HN2 both alky-
lated neuronal DNA, the genes speciﬁcally tar-
geted by HN2 were quite distinct from those
targeted by MAM. The most striking differ-
ence is that HN2 primarily targeted genes that
regulate protein turnover and apoptosis
(Figure 3D). Genes that inﬂuence the synthesis
(Metap2, Mobp), modification (Galnt9), or
degradation (Psme3) of neuronal proteins were
down-regulated by HN2 (Table 2). The
increased expression of apoptosis-inducing fac-
tor (Pdcd8), a flavoprotein that translocates
from the mitochondrial intermembrane space
to the nucleus to induce caspase-independent
DNA fragmentation of cerebellar neurons
(Slagsvold et al. 2003) and the targeting of sev-
eral mitochondrial genes (Cox7a2) suggests
that HN2-induced neuronal death results from
disturbances in mitochondrial function. A con-
comitant increase in the proteasomal 19s lid
component Psmd7 (or RPN8), which has dual
roles in both proteolysis and mitochondrial
integrity (Rinaldi et al. 2004), is consistent
with this mechanism. However, HN2 had the
greatest influence on adenine deaminase
(Ampd3), an enzyme that maintains steady-
state levels of ATP in CNS neurons (Knecht
Genotoxicants induce neuronal molecular signatures
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Figure 3. Effect of MAM and HN2 on global gene expression in cultured cerebellar neurons. Mouse cerebellar
granule cell cultures were treated with MAM (100 μM) or HN2 (1.0 μM) for 24 hr. (A) Gene expression changes
were induced by MAM or HN2. All genes with log2 MAM/control or HN2/control gene expression ratios > 1 or
< –1 were normalized by the absolute valued of the maximum fold change for the gene and grouped by hierar-
chical clustering using Euclidean distances. (n = 606 genes for MAM and 617 genes for HN2). (B) Venn dia-
gram depicting the overlap between MAM- and HN2-responsive genes. Up-regulated (red): numbers
represent all genes with signiﬁcant differences between MAM or HN2 and control-treated neurons and log2
(MAM or HN2/control) > 1. Down-regulated (green): signiﬁcant differences between MAM or HN2 and con-
trol-treated neurons and log2 (MAM or HN2/control) < –1. (C) Functional classes of the genes inﬂuenced by
MAM. (D) Functional classes of the genes inﬂuenced by HN2. Named genes with functional annotations in the
Unigene database (http://www.ncbi.nlm.nih.gov/UniGene) were categorized by broad functional class.
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–4 –2 0 2 4et al. 2001). Because increased AMPD activity
is associated with oxidative stress and disturbed
calcium homeostasis (Ronquist et al. 2001),
HN2 may also induce cell death by disturbing
neuronal ATP pools. The concomitant inﬂu-
ence of HN2 on Ca2+-dependent enzymes
(Calm1, Calm2) may have contributed to the
increased expression of AMPD (Mahnke and
Sabina 2005).
Although MAM and HN2 targeted dis-
tinct neuronal genes, there were a number of
genes that were common targets for both geno-
toxicants (Table 3). As shown in Table 3, a
majority of the genes targeted by both MAM
and HN2 were down-regulated. The func-
tional classes of genes speciﬁcally targeted by
both genotoxicants were also quite distinct
from those targeted by each genotoxicant. The
strongest response was observed for genes
involved in transport (5.7%), development
(2.9%), and transcription (2.9%). The target-
ing of these genes by both genotoxicants may
be a signature of a generalized response of neu-
rons to DNA-damaging agents. 
Transcriptional regulatory network
analysis. We further analyzed microarray data
using the promoter analysis tool PAINT
(promoter analysis and interaction network
tool) (Vadigepalli et al. 2003) to identify the
biologically relevant transcription factor bind-
ing sites within the regulatory regions of the
genes targeted by HN2 and MAM. Using the
unique genes differentially regulated by at
least a factor of two after MAM (n = 115) or
HN2 treatment (n = 136), we examined the
5´-flanking regions of these targeted genes
(2000 bp upstream of the transcription start
site) for enrichment of commonly expressed
transcriptional regulatory elements (TRE).
The total number of TREs among the unique
genes targeted by MAM (n = 78) was greater
than those targeted by HN2 (n = 60). Only
TREs that were significantly enriched
(p < 0.01) in either MAM- or HN2-targeted
genes (Figure 4A and 4B, respectively) and
occurring in at least 5% of the promoters are
shown. Note that no overlap occurred
between the TREs enriched in the promoter
regions of genes targeted by MAM and HN2
(compare Figure 4A,B). Several MAM-
targeted genes were highly enriched for SRF,
Nrf2, and Pax6, whereas Staf, HNF1 and
Cre-BP1 were primarily enriched in HN2-
targeted genes. SRF is required for neuronal
activity–induced gene expression and synaptic
plasticity (Ramanan et al. 2005), Nrf2 is a key
regulator of oxidative stress and chemical car-
cinogen inducible genes (Motohashi and
Yamamoto 2004) and Pax6 controls the
polarization and migration of CNS neurons
(Yamasaki et al. 2001). Several genes involved
in neuronal differentiation and migration
(e.g., Pafah1b2, Stmb2, Actb, Sdrf1, Pex1)
were highly enriched with these TREs, thereby
suggesting that these regulatory regions may
be important targets by which MAM disrupts
cerebellar development. In contrast, Staf,
HNF1, and Cre-BP1 (or ATF2) were espe-
cially enriched in HN2-targeted genes
involved in protein turnover (e.g., Cstf2), the
cellular response to DNA damage (Ishiguchi
et al. 2004), or cell death mechanisms
(Pearson et al. 2005). The enrichment of dis-
tinct TREs within MAM- or HN2-targeted
genes is additional evidence that these two
genotoxicants exert their influence on gene
expression in immature neurons by different
mechanisms.
Kisby et al.
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Table 1. Selected MAM-responsive genes in cerebellar neurons.
GenBank Fold change 
accession no. Gene name Gene symbol (MAM/control)a Summary function
Highest response to MAM
AI846799 H3 histone, family 3A H3f3a 3.77 Replacement histone
AI841944 protein kinase C, zeta Prkcz 3.74 Neurite extension
AI850194 Unc-51 like kinase 1  Ulk1 3.47 Granule cell axon extension
AI847913 proﬁlin 2 Pfn2 3.10 Actin polymerization
Neuronal function
AI836607 vesicle-associated membrane protein 4 Vamp4 2.40 Vesicular trafﬁcing
AI847695 kinesin heavy chain member 1A Kif1a 2.35 Molecular motor
BG085187 neurochondrin Ncdn 2.32 Dendritic outgrowth
AI854735 complexin 2 Cplx2 2.08 Synaptic vesicular release
Development
A1839566 stromal derived factor receptor Sdfr1 2.80 Axonal elongation
AI838741 platelet-activating factor acetylhydrolase, isoform 1b, alpha2 subunit Pafah1b2 2.79 Neuronal migration
AI838754 insulin-like growth factor binding protein 6 Igfbp6 2.60 Cerebellar folia
AI842688 stathmin-like 2 Stmb2 2.45 Microtuble stability
AI839303 zinc ﬁnger protein of the cerebellum 4 Zic4 2.25 Neurogenesis
Apoptosis control
BG077775 tumor necrosis factor receptor superfamily, member 23 Tnfrsf23 3.13 Apoptosis control
AI834850 amino-terminal enhancer of split Aes 2.71 NF-kappaB co-repressor
Ubiquitin-proteasome pathway
AI838669 proteasome (prosome, macropain) 26S subunit, non-ATPase, 12 Psmd12 2.75 19S lid component (RPN5)
AI847905 ubiquitin speciﬁc protease 5 (isopeptidase T) Usp5 2.60 Deubiqutinating enzyme
AI850551 ubiquitin fusion degradation 1 like Ufd1l 2.43 Polyubiquitin binding
AI843395 ubiquitin speciﬁc protease 21 Usp21 2.07 Deubiquitinating enzyme
Growth and cell cycle control
AI841459 diazepam binding inhibitor Dbi 2.53 Lipid metabolism
AI836597 microtubule-associated protein, RP/EB family Mapre2 2.06 Mitotic microtubules
AI323871 cyclin D3 Ccnd3 2.06 Neurite outgrowth
AI846429 U7 snRNP-speciﬁc Sm-like protein Lsm10 2.02 Histone mRNA processing
Miscellaneous genes of interest
AI849325 isocitrate dehydrogenase 3 (NAD+), gamma Idh3g 2.97 Mitochondrial respiration
AI840067 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1  Ndufc1 2.67 Mitochondrial respiration
AI836137 pyruvate kinase 3 Pk3 2.57 Glycolysis
AI838954 catenin alpha 1 Catna1 2.35 Axonal reorganization
AI853920 NADH dehydrogenase (ubiquinone) Fe-S protein 5 Ndufs5 2.33 Mitochondrial respiration
AI839652 t-complex protein 1, related sequence 1 Tcp1-rs1 2.33 Chaperonin protein
AI839531 solute carrier family 25, member 12 Slc25a12 2.01 Mitochondrial Asp/Glu transporter
AI323840 enhancer of zeste homolog 2  Ezh2 2.01 Histone lysine methyltransfease
NCBI GenBank database (http://www.ncbi.nlm.nih.gov/) was used to obtain gene name, gene symbol, and summary function.
aThe fold changes between MAM- and control-treated neurons were statistically signiﬁcant at fals discovery rate of 0.05 after adjustment for multiple comparisons.Discussion
Increasing evidence indicates that biomarkers
of genetic damage (including DNA lesions)
occur in children and newborns exposed to
environmental pollutants (Neri et al. 2006).
A consistent ﬁnding among these studies is the
frequent association between the level of DNA
lesions and impaired growth during the pre-
natal or postnatal period. The increased level
of genetic damage reported in these children
could also have important adverse health
effects on the brain, especially during early
development. Consistent with this hypothe-
sis, we have recently shown that DNA dam-
age (i.e., N7-mG) and the perturbation of
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Table 2. Selected HN2-responsive genes in cerebellar neurons.
GenBank Fold change
accession no. Gene name Gene symbol (HN2/control)a Summary function
Highest response to HN2
BG080773 AMP deaminase 3 Ampd3 4.10 Purine metabolism
BG066562 proteasome (prosome, macropain) 26S subunit, non-ATPase, 7 Psmd7 3.86 Protein degradation
C87546 serine/threonine kinase 11 Stk11 3.83 Cell cycle and polarity
BG086264 polymerase (RNA) II, DNA directed  Polr2 –3.27 RNA synthesis
Neuronal function
AI850277 neuromedin Nmu 2.03 Locomotor and stress response
A1848307 staufen homolog 2 Stauf2 –2.14 RNA transport
AI847890 proteolipid protein  Plp –2.16 Myelination
Development
BG088163 split hand/foot deleted gene 1 Shfdg1 3.08 DNA repair
AU021923 jagged 1 Jag1 2.61 Oligodendrocyte development
BG063365 chemokine (C-X-C motif) receptor 4 Cxcr4 2.39 Neural progenitors
AI847007 NCK-associated protein 1 Nckap1 –2.02 Cell motility
AI843136 N-myc downstream regulated 2 Ndr2 –2.23 Neural differentiation
Apoptosis control
C85471 programmed cell death 8 Pdcd8 2.69 Apoptosis control
BG086831 programmed cell death 4 Pdcd4 2.13 Apoptosis control
AI853558 tumor necrosis factor receptor superfamily, member 12a Tnfrsf12a –2.11 Nuclear factor-kappaB activation
Ubiquitin-proteasome pathway
BG085363 proteasome (prosome, macropain) 26S subunit, non-ATPase, 11 Psmd11 2.71 Proteasome (19S Lid)
AI843127 huntingtin interacting protein 2 Hip2 2.11 Ubiqutiin-conjugating enzyme
AU020960 proteaseome (prosome, macropain) 28 subunit, 3 Psme3 –2.41 Proteasome (20S alpha subunit)
Growth and cell cycle control
C86021 growth differentiation factor 9 Gdf9 3.61 Cell growth
AI853288 ras homolog gene family, member U Arhu 2.33 Signal transduction
BG072244 calmodulin 1 Calm1 2.13 Cell cycle
AI843756 calmodulin 2 Calm2 –2.16 Cell cycle
Miscellaneous genes of interest
AI851097 H1 histone family, member 2 H1f2 –2.36 Chromatin compaction
AI849019 myelin-associated oligodendrocytic basic protein Mobp –2.71 Stuctural components of myelin
GenBank database (http://www.ncbi.nlm.nih.gov/) was used to obtain gene name, gene symbol, and summary function.
aThe fold changes between HN2- and control-treated neurons were statistically signiﬁcant at false discovery rate of 0.05 after adjustment for multiple comparisons.
Table 3. Selected MAM- and HN2-responsive genes in mouse cerebellar neurons.
GenBank Fold changea
accession no. Gene name  Gene symbol MAM/control HN2/control Summary function
Highest response to MAM and HN2
AI836491 heat shock 10 kDa protein 1 (chaperonin 10) Hspe1 4.03 2.99 Mitochondrial chaperone
AI843553 heat shock 70kD protein 5 (glucose-regulated protein, 78kD) Hspa5 3.11 2.21 ER stress response
BG088092 solute carrier family 14, member 1 Slc14a1 –2.70 –2.10 Urea transport
AI847514 solute carrier family 1, member 3 Slc1a3 –2.86 –2.17 Glial glutamate transport
Development
AI841643 platelet derived growth factor, B polypeptide Pdgfb 3.01 2.54 Neuronal migration
AI846342 membrane-type frizzled-related protein Mfrp 2.58 2.39 Tissue polarity
AI838959 actin, alpha 2, smooth muscle, aorta Acta2 2.56 2.14 Cytoskeleton organization
Signal transduction/transport
AI835905 ferritin heavy chain Fth 2.63 2.19 Iron storage factor
AI836589 ATP synthase, H+ transporting mitochondrial F1 complex, beta subunit Atp5b 2.54 2.46 Mitochondrial transport
AI843291 synbindin Sbdn 2.41 2.16 Vesicular transport
AI842821 phospholipase C-like 2 Plcl2 2.15 2.12 Vesicular transport 
Transcription
AI837833 zinc ﬁnger protein 95 Zfp95 2.87 2.86 Transcription regulator
AI845485 four and a half LIM domains 4 Fhl4 2.65 2.07 Transcriptional co-activator
AI835325 kelch-like ECH-associated protein 1 Keap1 2.40 2.02 Transcription regulator
AI842684 interferon regulatory factor 3 Irf3 –2.01 –2.10 Transcription regulator
Miscellaeneous genes of interest
AI841630 ATP citrate lyase Acly 2.51 2.19 Acetyl-CoA synthesis
AI839804 CDC-like kinase 2 Clk2 2.02 2.08 Synaptic reorganization
BG081218 DNA cross-link repair 1A, PSO2 homolog (S. cerevisiae) Dclre1a –2.13 –2.27 DNA cross-link repair
BG069818 ubiquitin speciﬁc protease 3 Usp3 –2.43 –2.55 Deubiquitinating enzyme
BG075881 tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation  Ywhaz –2.48 –2.44 Cell adhesion
protein, zeta polypeptide
GenBank database (http://www.ncbi.nlm.nih.gov/) was used to obtain gene name, gene symbol, and summary function.
aThe fold changes between MAM- and control-treated and HN2- and control-treated neurons were statistically signiﬁcant at false discovery rate of 0.05 after adjustment for multiple comparisons.Kisby et al.
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developmentally regulated genes occurs well
before the neurodevelopmental changes
induced by the genotoxicant MAM (Kisby
et al. 2005). These studies suggest that DNA
damage may be responsible for the neurodevel-
opmental changes induced by the genotoxicant
MAM. Thus, our focus in the present studies
was to investigate the putative link between
genotoxicant-induced DNA damage and neu-
ronal function by identifying the genes in
immature neurons speciﬁcally targeted by dif-
ferent genotoxicants (i.e., MAM, HN2).
As shown in previous in vivo studies
(Kisby et al. 2005), we show here that imma-
ture cerebellar neurons (i.e., granule cells) are
very sensitive to genotoxicants and that this
effect was associated with the accumulation of
DNA lesions (i.e., N7-mG, GMOH). Our
studies also suggest that the DNA damage in
the cerebellum of MAM-treated neonatal mice
had accumulated in immature granule cells.
The greater sensitivity of granule cells compared
with astrocytes to either genotoxicant is evi-
dence that neurons are especially vulnerable to
genotoxicants and are inefﬁcient at repairing
DNA damage. This appears to be a characteris-
tic response of cerebellar neurons to genotoxi-
cants because granule cells are also very sensitive
to chemotherapeutic agents that alkylate DNA
(e.g., chloronitrosourea) or induce cross-links
(e.g., cisplatin) (Fujimori et al. 1992; Jones and
Gardner 1976; Wick et al. 2004), whereas glial
cell (e.g., astrocytes) loss is not commonly
found (Cattaneo et al. 1995; Necchi et al.
1997). This differential sensitivity to genotoxi-
cants is also shared by immature neurons and
astrocytes in other brain regions because
N7-mG DNA lesions persisted in the cerebrum
of neonatal rats after a single in utero injection
of MAM (Kisby et al. 1999) or related alkylat-
ing agents (Buecheler and Kleihues 1977;
Kleihues and Bucheler 1977), whereas glial
changes were unremarkable (Eriksdotter-
Nilsson et al. 1986). Thus, these in vitro studies
complement previous in vivo work by demon-
strating that the DNA of immature neurons
appears to be an important target for genotoxi-
cants. Moreover, the inefficient removal of
DNA lesions in granule cells could also explain
why the cerebellum is speciﬁcally targeted by
genotoxicants (Fonnum and Lock 2000;
Jirakulsomchok et al. 1982; Mehl et al. 2000;
Singh et al. 1983; Smith et al. 1987) and why
cerebellar function is disturbed in both neuro-
developmental and DNA repair disorders
(Fiore et al. 2004; Wallace et al. 2003).
As noted above, DNA lesions appear to
persist in immature neurons of genotoxicant-
treated animals. This could explain why the
developing cerebellum is a prime target in sev-
eral human neurodevelopmental disorders
(Ahsgren et al. 2005; Bauman and Kemper
2005; Guerrini and Filippi 2005; Hatten
2002). Because DNA lesions (e.g., alkyl or
bulky) can inﬂuence gene transcription either
up or down, depending on the sequence con-
text (Scicchitano et al. 2004), it is conceivable
that the DNA lesions formed by MAM or
HN2 profoundly inﬂuenced the expression of
developmentally regulated neuronal genes. Like
previous microarray studies of the cerebellum
(Kisby et al. 2005), we show that MAM tar-
geted a large number of critically important
genes that control the maturation and differen-
tiation of neurons. However, little overlap
occurred between the genes targeted by HN2
and MAM, indicating that the different types
of DNA lesions (methyl vs. cross-links) pro-
duced by these genotoxicants could have been
an important contributing factor. This notion
is consistent with the distinct gene expression
profiles produced in murine cells after treat-
ment with various classes of genotoxicants. In
one study, methylating agents (e.g., methyl
methane sulfonate), cross-linking agents (e.g.,
mitomycin C), or agents that form bulky DNA
lesions (e.g., benzo[a]pyrene) were compared
and found to induce gene expression proﬁles
quite distinct from each other and other non-
genotoxicants (Newton et al. 2004). Hu and
colleagues (2004) reached similar conclusions
after examining the gene expression proﬁles of
murine lymphoma cells lines treated for 4 hr
and 20 hr with similar classes of genotoxicants.
Figure 4. Analysis of the promoter regions of gene sets from MAM and HN2 treated cerebellar neurons for
enriched transcriptional regulatory elements (TRE). The 5’-ﬂanking regions (2 kb) of genes that were differ-
entially regulated (factor > 2.0) in cerebellar neurons by MAM (A) or HN2 (B) were analyzed by PAINT v3.0
to identify overrepresented transcription regulatory elements (TREs). The genes (rows) and motifs
(columns) were individually clustered and a subset of those that were found in > 5% of all promoters were
used to generate an interaction matrix. Differences in color intensity (i.e., red) indicate the relative fre-
quency of each TRE among the gene sets. 
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Like the present study, they used concentra-
tions of genotoxicants that induced minimal
toxicity (10–30%) so as to avoid the activation
of cell death pathways. Therefore, our data
indicate that the distinct gene expression
changes induced by MAM or HN2 may be
due to the inﬂuence of DNA lesions produced
by these genotoxicants on transcription.
Recent microarray studies support this hypoth-
esis by showing that the decline in gene expres-
sion within the aging human brain is associated
with a corresponding increase in DNA lesions
(i.e., 8-oxodexoyguanosine) within the pro-
moter region of key genes involved in learning,
memory, and neuronal survival (i.e., synaptic
plasticity) (Lu et al. 2004). 
Studies on human neuronal migration dis-
orders indicate that defects in migration as
well as in proliferation, survival, and differen-
tiation may contribute to neurodevelopmental
disorders (Ross and Walsh 2001). The molec-
ular and genetic basis of neuronal migration
disorders suggests that the key steps depend on
proper actin, microtubule cytoskeletal alter-
ations as well as proper transduction of extra-
cellular signals by migrating neurons. One key
ﬁnding of the present studies is that the mole-
cular pathways controlling neuronal migration
and maturation were predominantly targeted
by MAM but not by the related genotoxicant
HN2. More speciﬁcally, MAM had a signiﬁ-
cant influence on several genes that control
the development of neuronal processes (i.e.,
axons, dendrites) that would markedly impair
neuronal growth cone motility and its
pathﬁnding ability (Hatten 1999). The prefer-
ential targeting of neuronal differentiation by
MAM is also consistent with the ability of this
genotoxicant to disrupt unique molecular net-
works during either fetal (Hoffman et al.
1996) or postnatal (Kisby et al. 2005) neu-
ronal development. The unexpected strong
inﬂuence of MAM on several genes involved
with chromatin remodeling or energy metabo-
lism suggests that these cellular processes may
play an important role in the ensuing neu-
rodevelopmental deﬁcits. Consequently, early-
life exposure to genotoxicants would be
expected to have a pronounced influence on
neuronal development and thus, induce long-
term changes in CNS function. 
In summary, the present studies demon-
strate that immature neurons are especially vul-
nerable to genotoxicants and that this
vulnerability is associated with the accumula-
tion of speciﬁc DNA lesions and distinct alter-
ations in gene expression. The preferential
targeting of genes involved in such diverse func-
tions such as differentiation, stress and immune
response, cell signaling, transcriptional regula-
tion by MAM and apoptosis and protein syn-
thesis by HN2 suggests that genotoxicants
target distinct neuronal networks and they are
likely to induce completely different effects on
the developing brain. This is supported by the
increased vulnerability of mature neurons to
HN2 (Sullivan et al. 1982) but not to MAM
(Sullivan-Jones et al. 1994). The preferential
targeting of apoptotic networks by HN2 sug-
gests that cross-links (formed between two
opposing GMOH DNA lesions) are more
likely to activate cell death mechanisms.
Consequently, the targeting of speciﬁc molec-
ular networks by different gentoxicants
may explain the differential response of the
developing CNS to different genotoxicants. 
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